Recombinant adenovirus vaccines
AssigneeWyeth
InventorsAlan R. Davis, Michael D. Lubeck, Robert J. Natuk, Pranab K. Chanda, Shridhara C. S. Murthy, Shaw-Guang L. Lee, Paul P. Hung
Life of this patent
Estimating the term…
Loading patent…
AssigneeWyeth
InventorsAlan R. Davis, Michael D. Lubeck, Robert J. Natuk, Pranab K. Chanda, Shridhara C. S. Murthy, Shaw-Guang L. Lee, Paul P. Hung
Estimating the term…
This invention provides a method of protecting a primate from an infectious organism by stimulating the production of antibodies or cell mediated immunity to the infectious organism which comprises administering to said primate intranasally, intramuscularly, or subcutaneously, live recombinant adenoviruses in which the virion structural protein is unchanged from that in the native adenovirus from which the recombinant adenovirus is produced, and which contain the gene coding for the antigen corresponding to said antibodies or inducing said cell mediated immunity. Preferably, the infectious organism is HIV and the primate is a human.
A method of protecting a primate against HIV-1 infection comprising intranasal or intramuscular administration to said primate of an intranasal or intramuscular dosage of a recombinant adenovirus having a deletion in the E3 gene and an expression cassette containing a major late promoter, a tripartite leader sequence, part or all of the HIV-1 gp160 sequence and a polyadenylation signal sequence, said cassette being inserted into said recombinant adenovirus between the E4 promoter and the inverted terminal repeat of said recombinant adenovirus.
A method of protecting a primate against HIV-1 infection comprising the steps of (i) intranasal or intramuscular administration to said primate of an intranasal or intramuscular dosage of a recombinant adenovirus serotype 4, 5 or 7 having a deletion in the E3 gene and an expression cassette containing a major late promoter, a tripartite leader sequence, part or all of the HIV-1 gp160 sequence, part of all of the coding sequence for the HIV-1 rev gene inserted in frame after the HIV-1 gp160 sequence and a polyadenylation signal sequence, said cassette being inserted into said recombinant adenovirus between the E4 promoter and the inverted terminal repeat of said recombinant adenovirus;
Dependencies are inferred from the claim text.